Sanguine Diagnostics & Therapeutics Inc.

Omaha, NE

UEI
ECGMLSHGH4X6
CAGE
5QS80
Primary NAICS
Not on record
SAM.gov registration
Active through

Company facts

Self-certified in SAM.gov
  • For Profit Organization
  • Subchapter S Corporation
Entity structure
Corporate Entity (Not Tax Exempt)
SAM.gov registration date
Physical address
601 S Saddle Creek Rd Rm 7060, Omaha, NE 68106, USA

Registration and certifications come from SAM.gov and the SBA; company details from public web sources. Updated .

Grant awards

Award Agency Obligated Awarded
Combinatorial biomarkers for malignant polyps and colon cancer detection R43CA235984 National Cancer Institute (NIH) $225,000
Seromic mucin signature for the early diagnosis of pancreatic cancer R44CA224619 National Cancer Institute (NIH) $1,452,790
MUC4/16 assay for the early diagnosis and management of benign and malignant pancreatic diseases R44DK117472 National Institute of Diabetes and Digestive and Kidney Diseases (NIH) $1,369,737
Ultrasensitive sers nano-sensors for pancreatic cancer diagnosis and prognosis R41CA213718 National Cancer Institute (NIH) $300,000
Mucins in the diagnosis and prognosis of pancreatic diseases R41CA177288 National Institutes of Health $225,000

Quick answers

Is Sanguine Diagnostics & Therapeutics Inc. registered in SAM.gov?

Yes. Sanguine Diagnostics & Therapeutics Inc.'s SAM.gov registration is active through May 27, 2027.

What is Sanguine Diagnostics & Therapeutics Inc.'s most recent federal award?

Sanguine Diagnostics & Therapeutics Inc.'s most recent federal grant award is Combinatorial biomarkers for malignant polyps and colon cancer detection (R43CA235984), from National Cancer Institute (NIH), on March 1, 2019.

On GovTribe

See Sanguine Diagnostics & Therapeutics Inc.'s full federal record

  • Federal grant awards
  • Funding analysis by agency, NAICS and set-aside
  • Similar vendors
Try for free Login